The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1615
ISSUE1615
January 11, 2021
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
January 11, 2021 (Issue: 1615)
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza — Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved for
treatment of acute uncomplicated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.